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APOE ε4 is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) and
accounts for 50–65% of late-onset AD. Late-onset AD patients carrying or not carrying
APOE ε4 manifest many clinico-pathological distinctions. Thus, we applied a weighted
gene co-expression network analysis to identify specific co-expression modules in AD
based on APOE ε4 stratification. Two specific modules were identified in AD APOE ε4
carriers and one module was identified in non-carriers. The hub genes of one module
of AD APOE ε4 carriers were ISOC1, ENO3, GDF10, GNB3, XPO4, ACLY and MATN2.
The other module of AD APOE ε4 carriers consisted of 10 hub genes including ANO3,
ARPP21, HPCA, RASD2, PCP4 and ADORA2A. The module of AD APOE ε4 non-
carriers consisted of 16 hub genes including DUSP5, TNFRSF18, ZNF331, DNAJB5 and
RIN1. The module of AD APOE ε4 carriers including ISOC1 and ENO3 and the module of
non-carriers contained the most highly connected hub gene clusters. mRNA expression
of the genes in the cluster of the ISOC1 and ENO3 module of carriers was shown to be
correlated in a time-dependent manner under APOE ε4 treatment but not under APOE
ε3 treatment. In contrast, mRNA expression of the genes in the cluster of non-carriers’
module was correlated under APOE ε3 treatment but not under APOE ε4 treatment. The
modules of carriers demonstrated genetic bases and were mainly enriched in hereditary
disorders and neurological diseases, energy metabolism-associated signaling and G
protein-coupled receptor-associated pathways. The module including ISOC1 and ENO3
harbored two conserved promoter motifs in its hub gene cluster that could be regulated
by common transcription factors and miRNAs. The module of non-carriers was mainly
enriched in neurological, immunological and cardiovascular diseases and was correlated
with Parkinson’s disease. These data demonstrate that AD in APOE ε4 carriers involves
more genetic factors and particular biological processes, whereas AD in APOE ε4 non-
carriers shares more common pathways with other types of diseases. The study reveals
differential genetic bases and pathogenic and pathological processes between carriers
and non-carriers, providing new insight into the mechanisms of the differences between
APOE ε4 carriers and non-carriers in AD.
Keywords: Alzheimer’s disease, APOE ε4, APOE ε4 carriers and non-carriers, weighted gene co-expression
network analysis (WGCNA), hub gene cluster
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INTRODUCTION
Alzheimer’s disease (AD) is one of the leading causes of dementia
and is characterized by cognitive decline with distinctive brain
pathology such as amyloid plaques and neurofibrillary tangles
(Selkoe, 2003). Rare familial AD (FAD) is an early onset disease
and is caused by several definite and specific genes, such as
amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1,
PSEN2) (Scheuner et al., 1996; Campion et al., 1999). In contrast,
the etiology of the most common form of non-familial late-onset
AD appears to be more complicated. Thus far, many genetic loci
have been identified to be risk factors of late-onset AD through
genome-wide association studies (GWAS) (Harold et al., 2009;
Naj et al., 2011; Kauwe et al., 2014). Moreover, alterations in
many molecules and biological processes have been recognized
in AD (Mattson, 2004). A biological process may involve dozens
and even hundreds of molecules, and a molecule may participate
in multiple biological processes. It seems impractical to uncover
the relationships among all of these molecules and biological
processes one by one. Thus, the exploration of the pathogenic and
pathological mechanisms of AD in a systematic view may be more
appropriate.
APOE is the strongest susceptible gene of late-onset AD
(Wijsman et al., 2011). APOE exists as three polymorphic alleles
ε2, ε3, and ε4. Individuals with one or two copies of APOE
ε4 have a higher risk of developing AD than the carriers
of other isoforms (Corder et al., 1993). AD patients carrying
or not carrying APOE ε4 manifest many clinico-pathological
distinctions. Patients who are APOE ε4 carriers perform worse
on memory tasks than non-carriers (Marra et al., 2004). Patients
of APOE ε4 non-carriers exhibit impairments in naming, mental
speed and executive function (van der Vlies et al., 2007; Wolk
et al., 2010). A positron emission tomography study indicated
different perfusion profiles in the brains of APOE ε4 carriers and
non-carriers during a working memory task (Scarmeas et al.,
2004). Moreover, AD APOE ε4 carrier’s display significantly
reduced blood flow in the temporal and hippocampal areas
(Suwa et al., 2015). In addition, APOE ε4 carriers have greater
amyloid deposition and APOE ε4 can predict the atrophy rates
across brain regions affected by AD (Jack et al., 2015; Hua
et al., 2016). Moreover, previous studies have demonstrated
that different drug responses are observed in APOE ε4 carriers
and non-carriers. A neuroprotective agent facilitating brain
noradrenergic and vasopressinergic activities have been shown to
improve the Minimum Mental State Examination (MMSE) score
in APOE ε4 carriers but not in non-carriers (Richard et al., 1997).
A higher dose of bapineuzumab, an anti-β-amyloid peptide (Aβ)
monoclonal antibody, is needed to decrease cerebrospinal fluid
phospho-tau concentration in APOE ε4 non-carriers than in
carriers (Salloway et al., 2014). All the evidence indicates that
different pathogenic and pathologic processes are involved in
the disease progression of AD patients with different APOE ε4
statuses. APOE ε4 has been shown to affect Aβ aggregation,
promote neurofibrillary tangle formation and impair synaptic
plasticity (Bu, 2009), which are all pathological hallmarks of
AD. However, these harmful effects of APOE ε4 do not fully
explain the clinico-pathological phenotypic distinctions between
APOE ε4 carriers and non-carriers of AD patients. Furthermore,
APOE ε4 only accounts for 50–65% of late-onset AD. Therefore,
patient stratification based on APOE ε4 status can allow for the
exploration of the underlying mechanisms of clinico-pathological
distinctions between APOE ε4 carriers and non-carriers and
may further help to elucidate the molecular mechanisms of AD
which could be masked when combining APOE ε4 carriers and
non-carriers together.
The transcriptome bridges the gap between genetic variation
and the function of the molecules. Knowing its structure permits
the exploration of the comprehensive function of molecules
that could be influenced by genetic and non-genetic factors.
With the availability of a transcriptome dataset (Webster
et al., 2009), we analyzed the transcription profiles of AD
patients based on APOE ε4 status by applying a systems
biology approach, weighted gene co-expression network analysis
(WGCNA) (Langfelder and Horvath, 2008). WGCNA allows
for the identification of groups of genes (called modules)
whose expression is highly correlated within a network. Then,
specific co-expression modules can be obtained by comparing the
modules identified in different sub-datasets. Using this method,
we identified different co-expression modules and revealed
different biological processes involved in AD APOE ε4 carriers
and non-carriers.
MATERIALS AND METHODS
Microarray Dataset
The microarray dataset was downloaded from Gene Expression
Ominibus (GEO)1. The dataset, GSE15222, measured on
GPL2700 using Illumina Sentrix Human Ref-8 Expression Bead
Chip which covers 24354 probesets consists of human cerebral
cortex samples of 188 controls and 176 patients with diagnosis
of late-onset AD. The original expression data were rank-
invariant by BeadStudio software available from Illumina and
the Illumina custom error model was used. Rank-invariant-
normalized expression data were log10 transformed, and missing
data were encoded as missing, rather than as a zero level of
expression. Chips with average detection scores less than 0.99
(5% of control chips, 8% of late-onset AD chips) were excluded
from the analysis. Transcripts that were detected in less than
90% of the case or 90% of the control series were excluded from
our study. Finally 8650 high quality transcripts were obtained
(Webster et al., 2009). Of the 188 controls, 40 were APOE ε4
carriers and 148 were non-carriers. Of the 176 patients, 121 were
APOE ε4 carriers and 55 were non-carriers.
Sub-dataset-specific Co-expression
Module Detection by WGCNA
The WGCNA package which provides a robust set of R functions
was used to detect sub-dataset-specific modules (Langfelder and
Horvath, 2008). GSE15222 was divided into four sub-datasets:
patients carrying APOE ε4, patients not carrying APOE ε4,
controls carrying APOE ε4 and controls not carrying APOE
1http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15222
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ε4. Outliers were filtered out using Euclidian distance as the
similarity measure and average linkage as an agglomeration
method. For each sub-group, subjects were clustered based on
their dissimilarity, and any arrays with average inter-subject
correlation less than 2 standard deviations below the mean were
removed. This process was repeated until no arrays needed to be
removed (Oldham et al., 2008). One outlier was detected in AD
APOE ε4 non-carriers and was excluded before the construction.
A demographic depiction of the subjects was performed to
examine the similarity of sub-datasets. To construct the network,
Pearson correlation coefficients were calculated for all possible
gene pairs, and then the coefficients were powered by an exponent
β in each sub-group stratified by APOE ε4 and phenotypes.
A high βmaintains high adjacencies but pushes lower adjacencies
toward zero. An optimal exponent β can reduce the false
positive rate within the network to the utmost extent (Zhang
and Horvath, 2005). The dynamic tree-cutting algorithm was
then used to identify modules after the summarization of similar
patterns of connectivity among genes as topological overlap
matrix (TOM) (Langfelder et al., 2008). Modules with similar
module eigengenes (ME) were merged together. Unsupervised
average linkage hierarchical clustering identified 18 modules in
AD APOE ε4 carriers, 21 modules in AD APOE ε4 non-carriers,
10 modules in control APOE ε4 carriers and 8 modules in control
APOE ε4 non-carriers. Next, consensus modules (AD APOE ε4
carriers and non-carriers, AD and control APOE ε4 carriers, and
AD and control APOE ε4 non-carriers) were constructed with a
similar procedure to that illustrated above. A detailed description
of consensus module construction can be found at the WGCNA
tutorial website2.
The modules constructed using the sub-dataset of AD APOE
ε4 carriers were compared with the consensus modules of AD
APOE ε4 carriers and non-carriers, and with the consensus
modules of AD and control APOE ε4 carriers to detect specific
modules of AD APOE ε4 carriers. The modules constructed using
the sub-dataset of AD APOE ε4 non-carriers were compared
with the consensus modules of AD APOE ε4 carriers and non-
carriers, and with the consensus modules of AD and control
APOE ε4 non-carriers to detect specific modules of AD APOE
ε4 non-carriers. Then, the module preservation statistic Zsummary
was utilized to further examine the sub-dataset-specificity of the
modules (Langfelder et al., 2011). Unlike the cross-tabulation
test, Zsummary takes into account both overlaps in module
membership and the density and connectivity patterns of the
modules. The following recommended significant thresholds
for Zsummary were adopted: Zsummary <2 implies no evidence
of module preservation, 2 < Zsummary < 10 implies weak to
moderate evidence of module preservation, and Zsummary > 10
implies strong evidence for module preservation. Greater module
preservation corresponds to lesser specificity of the module to
the sub-dataset. Thus, a Zsummary less than 2 indicates strong
evidence of specificity of the module, a Zsummary between 2 and
10 indicates modest evidence of specificity of the module and a
Zsummary more than 10 indicates no evidence of specificity of the
2http://labs.genetics.ucla.edu/horvath/htdocs/CoexpressionNetwork/Rpackages/
WGCNA/Tutorials/index.html
module. Module networks were graphically depicted using the
program Cytoscape3.
Then random samplings with two different levels (50 and
75%) were performed with each level carried out five times.
The criterion of replication is that more than 80% of genes
within one of the modules (violet, dark magenta and light cyan)
detected among the total samples should be included in one
module detected in random samplings. Moreover, modules that
were obtained from random samplings and whose genes are
overlapped more than 80% with violet, dark magenta or light cyan
modules should be AD APOE ε4 carrier or non-carrier-specific.
Hub genes were identified by WGCNA via measures of
intramodular connectivity and module membership (Zhang and
Horvath, 2005; Dewey et al., 2011; Langfelder et al., 2011; de Jong
et al., 2012). Intramodular connectivity measures how a given
gene is connected, or co-expressed, with the genes of a particular
module. Module membership measures the membership of the
i-th gene with respect to a given module. Hub genes tend
to own high values of intramodular connectivity and module
membership.
Module eigengene values adjusted for phenotype, age and sex
were used to test differential expression of conserved modules
between AD and control APOE ε4 carriers and between AD and
control APOE ε4 non-carriers, and the values adjusted for APOE
ε4 status, age and sex were used to test differential expressions
of conserved modules between AD APOE ε4 carriers and non-
carriers.
Hub Gene Complete Graph Detection
R package graph was utilized to detect whether there was/were
complete graph(s) comprised of hub genes in sub-dataset-specific
modules.
Primary Neuron Culture and Quantitative
RT-PCR
Primary neurons were derived from the hippocampus of
Sprague–Dawley (SD) rats at postnatal day 1 as previously
described (Kam et al., 2010). Neurons were plated at a density
of 2 × 106 cells/well on poly-L-lysine-treated 6-well plate. The
neurons were treated with recombinant human APOE ε4 or ε3
at a concentration of 5 µg/ml or without APOE treatment on
DIV19 and collected for RNA extraction after 24, 48, and 72 h
of treatment. Total RNA was extracted using a Total RNA kit 1
from Sigma (St. Louis, MO, USA). RNA was reverse transcribed
to synthesize cDNA by using M-MLV reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed
using SYBR Green (Roche Diagnostics, Basel, Switzerland).
GAPDH was used as the normalization control. The relative
mRNA levels were calculated by a comparative Cp value. The
primers used were: ENO3: sense: AGCTGCTACCTAGGCAC
TCT, antisense: GGTTCCGTCCAGCTCAATCA; GNB3: sense:
TTTCACTGGCCACGAGTCAG, antisense: CTCTCGTGGGAG
TAGGCTGT; XPO4: sense: GGAATTCAGCAGACGGGAGA,
antisense: TAGTGTTTTGGAGGGAGAAAATTCC; GDF10:
sense: AATCATCAAGGCTGCCCGAA, antisense: CTGGACC
3http://www.cytoscape.org
Frontiers in Aging Neuroscience | www.frontiersin.org 3 July 2016 | Volume 8 | Article 171
fnagi-08-00171 July 12, 2016 Time: 11:41 # 4
Jiang et al. WGCNA of Late-Onset AD
AGAACTCGTGCTT; ISOC1: sense: GCTGCACTAACAAAAC
GCCA, antisense: TCATGGGACGGCAGGATAGA; ACLY:
sense: GGTAAGCTGGTGCTTACGGA, antisense: TCTGGA
TGGCTGAGGTGGTA; DUSP5: sense: GCCGACATTAGCTCC
CACTT, antisense: GCCAAAGTTGGGAGAGACCA; TNFR
SF18: sense: CACGTGTCCCCGAGATACC, antisense: GTCCC
CCAGACGACACTTTT; DNAJB5: sense: CTCCTCACCGCA
GCACC, antisense: TTCTCCTCAGCGTTGGGTTC; HILPDA:
sense: GCCTGCACGATCTAGTGTGA, antisense: GCACTCC
TCTGGATGGATGG; TBC1D8: sense: TGTATTCTCCCATAGC
ATGTGGT, antisense: GTCTCCTCAGCGATCAGAGC; BDNF:
sense: ACTGTCCTGCTACCGCAGTTG, antisense: GGGTCGC
AGAACCGCTAAA; ST8SIA5: sense: ACTTCGTCTTCCGGTG
CAAT, antisense: GGAAGTCGTCCAGCATGTACT; CHST12:
sense: GGTCTCCTTCGCCAACTTCA, antisense: AGCATCC
TCATCCAGGGTCT; ATF5: sense: GTGCCTAGGGTACAGGA
GGA, antisense: GCAGAGGGGAGACCTAGACA; CSNK1D:
sense: CACCTCACAGATTCCCGGTC, antisense: GCTCTTG
GAGCCTGTCCATT; PLIN2: sense: ATTCGCCAGGAAGAAT
GTGC, antisense: TGGCATGTAGTGTGGAGCTG.
Functional Annotations of
Sub-dataset-specific Modules
Functional annotations of sub-dataset-specific modules were
obtained by applying ingenuity pathway analysis (IPA)4. IPA
is a large manually curated database of published information
on mammalian biology and diseases. It is widely used for high
quality gene set enrichment analyses. Fisher’s exact tests were
utilized to calculate the P-values for each functional annotation
by comparing the number of genes from the module of interest
that participated in the specified IPA term against the total
number of genes from the term in the background set (Khatri
et al., 2012).
GWAS Dataset Preparation and
Module-Based GWAS Signal Enrichment
Test
The GWAS (Myers) was carried out in the same population
as that of the microarray dataset we utilized, and the dataset
was directly downloaded from the Myers laboratory5. For
replication, the GWAS dataset from the Multi-Site Collaborative
Study for Genotype-Phenotype Associations in Alzheimer’s
Disease (GenADA) (Li et al., 2008) was downloaded from
dbGaP6, the GWAS dataset from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) (Mueller et al., 2005) was
downloaded from the ADNI database7, and the dataset from
the International Genomics of Alzheimer’s Project (IGAP)
(Lambert et al., 2013) was downloaded from http://www.pasteur-
lille.fr/en/recherche/u744/igap/igap_download.php.
We excluded single nucleotide polymorphisms (SNPs)
with a missing genotype rate > 0.1, a minor allele
4http://www.ingenuity.com
5http://labs.med.miami.edu/myers/LFuN/data%20ajhg.html
6http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000219.v1.p1
7http://adni.loni.usc.edu/
frequency (MAF) < 0.01 and a Hardy–Weinberg equilibrium
(HWE) < 0.001. Finally, after quality control, 364048, 431284,
and 567199 SNPs from the Myers, GenADA and ADNI datasets,
respectively, were included for APOE ε4 carriers, and 374149,
427678, and 566459 SNPs from the Myers, GenADA and ADNI
datasets, respectively, were included for APOE ε4 non-carriers.
GWAS dataset preparation and quality control procedures
were performed using the software package PLINK8, release
v 1.07 (Purcell et al., 2007). Processed data of IGAP were
downloaded from the following link: http://www.pasteur-
lille.fr/en/recherche/u744/igap/igap_download.php.
A previously reported procedure of GWAS signal enrichment
test, called i-GSEA4GWAS, was employed (Zhang et al., 2010).
First, the maximum -log(P-value) of the SNPs located between
20 kb upstream and downstream of a gene boundary was
assigned to represent the gene, and the min P-value method,
which does not excessively penalize large genes if causative
associations are proportionally more common in smaller genes,
has been widely used in systems biology (Baranzini et al., 2009;
Jia et al., 2010). Instead of the commonly used phenotype
label permutation, SNP label permutations were implemented
to generate the distribution of the enrichment score (ES), and
then the gene set’s significance proportion based enrichment
score (SPES) was calculated based on genes’ rank using the
following equation: SPES = k/K × ES, where k is the proportion
of significant genes of the gene set and K is the proportion of
significant genes of the total number of genes in the GWAS
(Zhang et al., 2010). Gene-length bias was eliminated by applying
adaptive permutation in PLINK before i-GSEA4GWAS. False
discovery rate was applied for multiple comparison correction.
Then, a comparative quantile-quantile (QQ) plot was used
to demonstrate the differences among all genes and genes
within the interested modules of APOE ε4 carriers, and the
genomic dispersion factor, λ, was used to assess the strengths of
genetic association signals and to quantify the differences when
compared with the signals of all genes. The comparative QQ plot
was produced by plotting the ranked -log10(P-value) against the
expected order statistic, −log10[i/(L+1)], where i is the rank for
each SNP P-value (1 = smallest and L = largest), and L is the
number of SNPs. Function estlambda() within the R package
GenABEL was utilized to estimate the genomic dispersion
factor λ. If a co-expression module was genetically associated,
significant SNPs within 20 kb upstream and downstream of the
gene boundaries within the module in the sub-group in which
it belongs (APOE ε4 carrier sub-group or APOE ε4 non-carrier
sub-group) were identified, and the significance of these SNPs in
its opposite sub-group were also calculated.
Phylogenetically Conserved Promoter
Motif Identification in Hub Genes of the
Complete Graph
The conserved promoter motif(s) was/were identified by
PhyloCon. PhyloCon, which stands for Phylogenetic Consensus,
is one of the first motif-finding algorithms to combine the power
8http://pngu.mgh.harvard.edu/∼purcell/plink/
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of phylogenetic conservation and gene co-regulation (Wang and
Stormo, 2003; Wang, 2007). PhyloCon first aligns conserved
regions of orthologous sequences into multiple sequence
alignments, or profiles, and then compares profiles representing
non-orthologous sequences. Then, motifs represented by
matrices or IUPAC strings emerge as common regions in these
profiles (Wang, 2007). An online web server named WebLogo
was used to generate the sequence logos of the motifs (Crooks
et al., 2004). In the present study, orthologous sequences of
the species Homo sapiens, Rattus norvegicus, Mus musculus,
and Canis lupus familiaris were utilized. For promoter regions,
the 4 kb segments centered on the annotated transcription
start site (TSS) of each human RefSeq gene were extracted
according to a previous study’s method (Xie et al., 2005). If
the annotated translation start codon was within 2 kb of the
TSS, the shorter region that did not overlap the protein-coding
sequence was selected. For genes with alternatively spliced
first exons, all promoters were included. Details for promoter
region detection are given in a previous study (Xie et al.,
2005).
JASPAR CORE database and miRWalk were utilized to
identify common human transcription factors (TFs), TF binding
sites (TFBS) and common miRNAs of the conserved motif(s)
and these highly connected genes. The JASPAR CORE database,
which contains a curated, non-redundant set of profiles, is
derived from published collections of experimentally defined
transcription factor binding sites for eukaryotes, The matrices
and IUPAC strings were then input into the JASPAR CORE
database to identify common human TFs and the TF binding
sites (TFBS) of these co-expressed genes (Mathelier et al.,
2014). miRWalk, a comprehensive database that incorporates
miRNA-targets interactions information produced by eight
established miRNA prediction programs on 3′ UTRs of all
known genes, was utilized to evaluate whether some miRNAs
exist as the common regulators of the mRNAs of genes within
the same complete graph post-transcriptionally (Dweep et al.,
2011). In the present study, five default prediction programs,
miRanda, miRDB, miRWalk, RNA22, and TargetScan, were
used. If a miRNA was predicted by at least two prediction
programs, it was regarded to bind to the gene with high
probability.
AD and Parkinson’s Disease (PD), Bipolar
Disease (BD) Consensus Pathogenic
Module Identification
GEO dataset GSE202959 for PD and GSE1265410 for BD were
extracted. The procedures for PD and BD co-expression network
construction and module detection were the same as those of
AD. Then, each PD- or BD-specific module was compared with
AD-specific modules via hypergeometric tests which examined
whether the number of genes overlapped between PD or
BD and AD was significantly larger than that expected by
chance.
9http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20295
10http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12654
RESULTS
Specific Co-expression Module
Detection in AD APOE ε4 Carriers and
Non-carriers
The demographic characteristics of the enrolled subjects
after excluding outlier samples demonstrated no differences
(Supplementary Table S1). By applying WGCNA, we identified
two specific co-expression modules (violet and dark magenta) in
AD APOE ε4 carriers and one module (light cyan) in AD APOE
ε4 non-carriers (Figure 1). The permutation-based preservation
statistic, Zsummary, demonstrated that the Zsummary statistics of
the identified three modules were all less than 2 when assessing
the violet and dark magenta modules of AD APOE ε4 carriers
in AD APOE ε4 non-carriers and control APOE ε4 carriers
and when assessing the light cyan module of AD APOE ε4
non-carriers in AD APOE ε4 carriers and control APOE ε4
non-carriers, showing no evidence of module preservation in
these sub-datasets (Figure 1; Supplementary Table S2). These
results strongly indicated that the three co-expression modules
were sub-dataset-specific. Network visualizations of the violet
and dark magenta modules in AD APOE ε4 carriers and the
light cyan module in AD APOE ε4 non-carriers are shown in
Figures 2A–C, respectively (Supplementary Tables S3–S5 for full
list of genes of violet, dark magenta and light cyan modules
respectively). The identified hub genes (most centered genes)
are shown in Supplementary Tables S3–S5. Moreover, six of
the seven hub genes (ISOC1, ENO3, GDF10, GNB3, XPO4 and
ACLY, Supplementary Table S3) of the violet module and all the
hub genes of the light cyan module (Supplementary Table S5)
were found to be highly connected as demonstrated to form a
complete graph respectively, which represents the most highly
connected gene cluster in biological network and tends to be
very important (Jeong et al., 2001; Horvath and Dong, 2008)
(Figure 2D; Supplementary Table S6 for the pairwise Pearson
correlation coefficients for the violet module and Figure 2E;
Supplementary Table S7 for the pairwise Pearson correlation
coefficients for the light cyan module).
Furthermore, we examined whether the non-specific co-
expression modules were differentially expressed between AD
and control APOE ε4 carriers, between AD and control APOE
ε4 non-carriers, and between AD APOE ε4 carriers and non-
carriers. In the results, no differences were found (data not
shown), demonstrating that these non-specific co-expression
modules were completely conserved.
Due to the unavailability of other AD-associated datasets with
APOEε4 status, we carried out random samplings for replication.
All three modules could be replicated (Supplementary Table S8).
Highly Connected Hub Genes Detected
in the Violet and Light Cyan Modules
Co-expressed in a Time-Dependent
Manner Dependent on APOE Types
The highly connected hub genes in the complete graph implicate
that the expression of these genes is correlated. Thus, we
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FIGURE 1 | Preservation statistic of modules detected in the test sub-dataset in the reference sub-dataset. The Zsummary = 2 and Zsummary = 10
thresholds are indicated by dashed lines. Zsummary less than 2 implies no evidence of module preservation, which indicates strong evidence of module specificity.
Zsummary between 2 and 10 implies modest evidence of module preservation and Zsummary more than 10 implies strong evidence of module preservation, which
indicates modest or no evidence of module specificity. (A) Module preservation of AD APOE ε4 carriers in AD APOE ε4 non-carriers; (B) Module preservation of AD
APOE ε4 carriers in control APOE ε4 carriers; (C) Module preservation of AD APOE ε4 non-carriers in AD APOE ε4 carriers; (D) module preservation of AD APOE ε4
non-carriers in control APOE ε4 non-carriers. See Supplementary Table S2 for exact Zsummary statistics.
examined the co-expression patterns of these genes in primary
cultured neurons treated with APOE ε3 or APOE ε4. As shown
in Figure 3A, the mRNA expressions of all six genes (ISOC1,
ENO3, GDF10, GNB3, XPO4 and ACLY) in the complete graph
of the violet module of AD APOE ε4 carriers demonstrated
a similar time-dependent patterns in neurons treated with
physiological concentration of APOE ε4, whereas, no such
patterns were observed in neurons treated with APOE ε3 or
in untreated neurons (Figures 3B,C). The pairwise Pearson
correlation coefficient matrix of the expressions showed the high
correlations between either two genes expressed in the APOE ε4-
treated neurons (Supplementary Table S9) with a mean absolute
Pearson correlation coefficient of 0.902, which is markedly higher
than the mean absolute Pearson correlation coefficients for
neurons treated with APOE ε3 (0.613) or for untreated neurons
(0.571) (Supplementary Tables S10 and S11 for the pairwise
Pearson correlation coefficient matrices for APOE ε3-treated
neurons and for untreated neurons, respectively). These results
confirm the co-expression of these six genes detected in the violet
module.
The mRNA expression of 12 genes in the complete
graph of light cyan module of AD APOE ε4 non-carriers
displayed similar or opposite time-dependent patterns in
primary cultured neurons treated with APOE ε3 (Figure 3E).
The pairwise Pearson correlation coefficient matrix showed
positive or negative correlations between most gene pairs
(Supplementary Table S12), with a mean absolute Pearson
correlation coefficient of 0.834. These results validated the
co-expression of genes in the complete graph of the light
cyan module. The co-expression patterns were much weaker
in neurons treated with APOE ε4 and in untreated neurons
(Figure 3D, Supplementary Table S13 for the pairwise Pearson
correlation coefficient matrix for APOE ε4-treated neurons and
Figure 3F, Supplementary Table S14 for untreated neurons, the
mean Pearson correlation coefficients were 0.616 and 0.629,
respectively).
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FIGURE 2 | Graphic visualization of modules and complete graphs identified in AD APOE ε4 carriers and non-carriers. (A–C) Graphic visualization of the
violet (A), and dark magenta (B) modules for AD APOE ε4 carriers and the light cyan module (C) for AD APOE ε4 non-carriers with hub genes. Nodes were filled with
different intermediate colors varying from red to ivory white, where red represents high intramodular connectivity and ivory white represents low connectivity. Edges
were weighted by the strengths of the connections between two nodes, for which shorter edges correspond to stronger relationships and vice versa. (D) Complete
graph of the top six hub genes in the violet module of AD APOE ε4 carriers. (E) Complete graph of the top sixteen hub genes in the light cyan module of AD APOE
ε4 non-carriers.
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FIGURE 3 | Time-dependent mRNA expression of genes within the complete graphs of the violet and light cyan modules. (A–C) The mRNA expression
of six genes within the complete graph of the violet module of AD APOE ε4 carriers. The legends of the six genes are shown on the right. (D–F) The mRNA
expression of twelve genes within the complete graph of the light cyan module of AD APOE ε4 non-carriers. The legends of the 12 genes are shown on the right.
The primary cultured neurons were treated with recombinant human APOE ε4 (A,D) or ε3 (B,E) at the concentrations of 5 µg/ml or without APOE treatment (C,F) on
DIV19 and collected for quantitative RT-PCR after 24, 48, and 72 h of treatment. The relative mRNA levels were calculated by a comparative Cp value. The data are
presented as the mean ± SD from at least three independent experiments.
Differential Biological Processes
Enriched in Specific Modules
Co-expressed genes in a module may directly interact with each
other or take part in the same biological processes and signaling
pathways. Hub genes within each module may play pivotal
roles in module function. Thus, IPA was employed for further
analysis.
As shown in Figure 4A, the genes of the violet module
identified in AD APOE ε4 carriers were enriched in hereditary
disorders, neurological diseases, psychological disorders, and
nervous system development and function (Supplementary
Table S15). The first two hub genes, ISOC1 and ENO3, were
enriched in the first annotation, hereditary disorders. These
two hub genes and another hub gene GNB3 were enriched in
neurological diseases (Supplementary Table S16). The primarily
enriched signaling pathways were acetyl-CoA biosynthesis III
(from citrate), NAD biosynthesis III, NAD salvage pathway
III and NAD biosynthesis from 2-amino-3-carboxymuconate
semialdehyde (Figure 4B; Supplementary Table S17), which
are mainly energy metabolism-associated signaling pathways.
Two relatively important energy metabolism-associated signaling
pathways, gluconeogenesis I and glycolysis I, were enriched
by the hub gene ENO3 (Supplementary Table S17). Genes of
the dark magenta module were mostly enriched in hereditary
disorders, neurological diseases, psychological disorders, and
G protein-coupled receptors (GPCRs) and second messenger-
associated signaling pathways of GPCRs (Figures 4C,D, see
Supplementary Tables S18–S20 for all enriched IPA terms). The
protein level of the hub gene, GAD2, which catalyzes glutamate
to γ-aminobutyric acid, has been reported to be reduced in some
cerebral regions of AD patients (Schwab et al., 2013).
Unlike the modules identified in AD APOE ε4 carriers, genes
of the light cyan module identified in AD APOE ε4 non-
carriers were enriched in some other types of diseases, such as
immunological and cardiovascular diseases, in addition to the
primarily enriched neurological diseases (Figure 4E, see also
Supplementary Table S21). The top-ranked hub gene, DUSP5,
was enriched in neurological diseases (Supplementary Table S22).
Moreover, another hub gene, BDNF, has been widely reported
to be related to AD (Tapia-Arancibia et al., 2008). Our analysis
also demonstrated that approximately 66% of enriched genes
found in either immunological or cardiovascular diseases were
also found in neurological diseases (Supplementary Figure S1).
However, genes within the two modules of AD APOE ε4 carriers
were not highly enriched in immunological and cardiovascular
diseases (Supplementary Tables S16 and S19). In addition, genes
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FIGURE 4 | Ingenuity pathway analysis (IPA) gene set enrichment analysis of the modules identified in AD APOE ε4 carriers and non-carriers.
IPA-identified top five diseases and functions (A,C,E) and top five canonical pathways (B,D,F) of the violet (A,B) and dark magenta (C,D) modules of AD APOE ε4
carriers and of the light cyan module (E,F) of AD APOE ε4 non-carriers. The verticals indicate the significant thresholds set by IPA.
of the light cyan module were mainly enriched in the following
signaling pathways: tRNA charging, endoplasmic reticulum (ER)
stress pathway, TR/RXR (thyroid hormone receptor/retinoid X
receptor) activation and TNFR1 (tumor necrosis factor receptor
type 1) signaling (Figure 4F; Supplementary Table S23).
Module-Based Enrichment of Genetic
Association Signals
Next, we examined whether the three sub-dataset-specific co-
expression modules had genetic bases. The violet module in
AD APOE ε4 carriers showed significant enrichment of signals
from the GWAS dataset of Myers of the corresponding APOE ε4
carriers in the gene expression data [P < 0.001 and P < 0.001
after false discovery rate (FDR) correction, Figure 5A]. Moreover,
the significant enrichment of signals was replicated in the
other two GWAS datasets of APOE ε4 carriers (P = 0.014
for the data from GenADA and P = 0.034 for the data
from ADNI, Figures 5B,C). The dark magenta module of AD
APOE ε4 carriers only showed a significant enrichment of
signals from the GenADA GWAS dataset of APOE ε4 carriers
(P = 0.015, Supplementary Figure S2). Comparative QQ plots
showed that genes within violet and dark magenta modules,
especially the violet module, deviated from the expected values
even further compared with the black dots, which represent all
genes (Figures 5D–F). The larger genomic dispersion factors
(λviolet and λdark magenta) further validated their genetic bases
(Figures 5D–F). Furthermore, genes in these two modules
showed significant enrichment of signals from the IGAP GWAS
dataset, which is the biggest AD-associated GWAS dataset to date
(FDR-corrected P-value < 1 × 10−4 for the violet module and
P-value = 0.009 for the dark magenta module, Supplementary
Figure S3). The QQ plots also showed a deviation of genes from
the expected values (Supplementary Figure S4). Moreover, almost
all significant SNPs within the 20 kb gene boundaries of the violet
module in APOE ε4 carriers were insignificant in non-carriers
(Supplementary Table S24). The light cyan module in AD APOE
ε4 non-carriers did not show a significant enrichment of signals.
Analysis of Possible Transcription
Modulation of Complete Graphs in
Specific Modules
Complete graphs were detected and validated in the violet
module of AD APOE ε4 carriers and in the light cyan module
Frontiers in Aging Neuroscience | www.frontiersin.org 9 July 2016 | Volume 8 | Article 171
fnagi-08-00171 July 12, 2016 Time: 11:41 # 10
Jiang et al. WGCNA of Late-Onset AD
FIGURE 5 | Genetic association signals for the violet and dark magenta modules of AD APOE ε4 carriers. (A–C) Manhattan plots of the enrichment
analyses of the genetic association signals from the Myers GWAS (A), GenADA GWAS (B), and ADNI GWAS (C) datasets for the violet module of AD APOE ε4
carriers. The green dots represent genes within the violet module. (D–F) Comparative QQ plots of the genetic association signals from the Myers GWAS (D),
GenADA GWAS (E) and ADNI GWAS (F) datasets for the violet and dark magenta module of AD APOE ε4 carriers. The black dots represent all genes, the violet
dots represent genes within the violet module and the dark magenta dots represent genes within the dark magenta module. Values of the genomic dispersion factor
λ are given in the top-left of each comparative QQ plot.
of AD APOE ε4 non-carriers, suggesting common transcription
modulation. Thus, we first identified conserved promoter
motif(s) by employing promoter homologous sequences of
these genes from four species, Homo sapiens, Rattus norvegicus,
Mus musculus, and Canis lupus familiaris. Two conserved
promoter motifs with extremely low conservative P-values
(P= 6.539× 10−122 for the 49-base motif and P= 1.003× 10−74
for the 14-base motif) were detected for the genes of the
complete graph of the violet module of AD APOE ε4 carriers
(Figures 6A,B), and an adenine-rich conserved promoter motif
was identified with a P-value of 1.935 × 10−125 among the genes
of the complete graph of the light cyan module of AD APOE ε4
non-carriers (Figure 6C).
Then, common human TFs of two motifs in the violet module
were identified (Table 1). Interestingly, two TFs, ZNF263 and
ESR1, were shared by the two motifs, and SNPs within ESR1
have been widely reported to be associated with AD (Mattila
et al., 2000; Corbo et al., 2006). RREB1, a TF of 49-base motif,
which can potentiate the transcriptional activity of NeuroD1/β2
(Ray et al., 2003), has been reported to be related with AD and
potentially with the NFκB1 gene (Pasluosta et al., 2011). Another
neuro-associated TF of 49-base motif, named REST, which can
repress neuronal genes in non-neuronal tissues (Yeo et al., 2005),
has been demonstrated to both silence and repress neuronal genes
(Greenway et al., 2007). SNPs proximal to TP63, a TF of 14-
base motif, which is present in the aging human hippocampus
(Yang and Wang, 1994), are reported to be associated with brain
morphometric measures of AD (Shen et al., 2010). Another TF
of 14-base motif, named EGR1, up-regulates the PSEN2 gene
in neuronal cells (Renbaum et al., 2003). However, currently
no highly scored human TFs could be predicted for the motif
identified in the light cyan module of AD APOE ε4 non-
carriers.
Furthermore, we investigated whether the mRNAs of these
genes in the complete graph could be regulated by some common
miRNAs. For the six genes in the violet module of AD APOE
ε4 carriers, hsa-miR-194, hsa-miR-199a-5p, hsa-miR-199b-5p,
hsa-miR-30a, hsa-miR-30d, and hsa-miR-30e were indicated to
bind with at least four of the five hub genes except GNB3
(Supplementary Table S25). hsa-miR-194 has been reported to
be down-regulated in white matter of AD patients and to
be negatively associated with neurofibrillary tangles in gray
matter and in neuritic plaques and neurofibrillary tangles in
white matter of AD patients (Wang et al., 2011). miRNAs
in the hsa-miR-199 family have been shown to target genes
involved in neurodegenerative diseases (Roshan et al., 2009).
Five members of the miR-30 family are up-regulated in AD
patients (Leidinger et al., 2013). However, currently no highly
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FIGURE 6 | Conserved promoter motifs of genes within the complete graphs of the violet and light cyan modules. WebLogo representations of
conserved promoter motifs in the violet module (A,B) of AD APOE ε4 carriers and in the light cyan module (C) of AD APOE ε4 non-carriers. The height of a letter at a
particular position is proportional to the frequency of that nucleotide substitution in that position.
TABLE 1 | Human TFs predicted for the two conserved promoter motifs in the violet module.
Motif TF name Class Family Score Percent score
49-base motif ZNF263 Zinc-coordinating ββα-zinc finger 36.811 87.646
RREB1 Zinc-coordinating ββα-zinc finger 33.664 84.161
ESR1 Zinc-coordinating Hormone-nuclear receptor 33.618 84.045
REST Zinc-coordinating ββα-zinc finger 32.833 78.173
PAX5 Helix-turn-helix Homeo 32.654 85.931
14-base motif SP2 Zinc-coordinating ββα-zinc finger 24.495 87.483
ESR1 Zinc-coordinating ββα-zinc finger 23.501 83.933
TP63 Zinc-coordinating Loop-sheet-helix 23.084 82.443
ZNF263 Zinc-coordinating ββα-zinc finger 23.082 82.435
EGR1 Zinc-coordinating ββα-zinc finger 22.879 81.711
Top five predicted human TFs of the 49-base motif and 14-base motif from complete graph of violet module of AD APOE ε4 carriers.
scored common miRNAs were predicted for the genes in the
complete graph of the light cyan module of AD APOE ε4 non-
carriers.
Correlated Modules between AD and PD
Parkinson’s disease is also a neurodegenerative disorder with
Lewy bodies deposited in neurons. Approximately 41.3% of
PD patients are complicated with dementia according to a
large population-based investigation (Mayeux et al., 1992).
Pathologically, many PD patients show senile plaques and
fibrillary tangles within the cerebral cortex (Boller et al., 1980),
and many AD patients display Lewy bodies in cortical and
subcortical regions (Hansen et al., 1990). BD is associated
with an increased risk of dementia (Wu et al., 2013). Some
symptoms and neuropathology of AD and BD overlap, such as
brain atrophy, cognitive impairment, and emotional disturbances
(Rao et al., 2012), however, no plaques and fibrillary tangles
have been reported to be characteristic of BD. Thus, to further
validate the identified modules, we applied the WGCNA analysis
to these two neurological diseases to investigate whether the
three identified co-expression modules were related to these
diseases.
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FIGURE 7 | Correlation between purple module of PD patients and
light cyan module of AD APOE ε4 non-carriers. (A) The overlapped
gene numbers between these two modules shown in a venn diagram.
(B,C) The top-shared diseases and functions (B) and canonical pathways
(C) between the two modules. The verticals indicate the significant
thresholds set by IPA.
Transcriptomic data from three brain regions– Brodmann
area 9 (BA9) of the prefrontal cortex, the putamen (PT) and the
entire substantia nigra (SN) of PD patients were available for
analysis. Among the detected PD-specific co-expression modules,
only the purple module detected in BA9 of the prefrontal
cortex which is the most PD-specific module (Supplementary
Figure S5) was significantly correlated with the light cyan
module of AD APOE ε4 non-carriers with an extremely low
P-value (Figure 7A, P = 9.522 × 10−24, Supplementary Table
S26 for detailed overlapped genes). Two of the overlapping
genes, DUSP5 and TBC1D8, were hub genes of the light
cyan module, and DUSP5 was the top hub gene of the light
cyan module (Supplementary Table S5). Furthermore, many
annotations were the same between the two modules. The top
diseases and functions and canonical pathways enriched in the
light cyan module were also enriched in the purple module
(Figures 7B,C). However, no BD-specific modules were found
to be related to the three modules identified in AD (data not
shown).
DISCUSSION
Unlike the analysis at the single-gene level, which can
be influenced by co-expressed genes and thus give biased
information, WGCNA, a systems biology approach which
identifies co-expression gene modules, may better uncover the
pathogenic and pathological mechanisms of complex diseases.
In the present study, we identified two specific co-expression
modules (violet and dark magenta) in AD APOE ε4 carriers and
one specific module (light cyan) in AD APOE ε4 non-carriers.
The most highly connected hub gene clusters (complete graph)
were further identified in the violet and light cyan modules.
Furthermore, the expression of these highly connected hub genes
in the violet module was demonstrated to be correlated time-
dependently under APOE ε4 treatment, whereas the expression
of genes in the light cyan module was highly correlated time-
dependently under APOE ε3 treatment. These experimental data
verified the results of the WGCNA and further demonstrated the
specificity and existence of the identified gene clusters.
The functional analysis of the identified modules in AD APOE
ε4 carriers and non-carriers showed that the identified modules
were enriched in distinct biological functions and signaling
pathways, demonstrating that different biological processes could
take part in disease progression with different APOE ε4 statuses,
and thus they likely underlie distinctive clinical and pathological
manifestations. Moreover, the expression patterns of conserved
modules were the same in the AD APOE ε4 carriers and non-
carriers. These results further highlight the significance of the
three identified modules in the distinct characteristics between
AD APOE ε4 carriers and non-carriers.
Our analysis demonstrated that the genes in both the violet
and dark magenta modules of AD APOE ε4 carriers were strongly
enriched in hereditary disorders, which was listed as the first
among the diseases and functions of the IPA annotations. More
importantly, a further analysis of enrichment with GWAS signals
demonstrated that the expression patterns of these two modules
had genetic bases in APOE ε4 carriers. Moreover, the significant
SNPs of genes within both modules could not be replicated in
APOE ε4 non-carriers. All these results demonstrated the genetic
basis of APOE ε4 carriers for the development of AD.
The most highly connected hub gene cluster in the violet
module was demonstrated to contain two phylogenetically
conserved promoter motifs which could be targeted by some
common TFs. Moreover, the mRNAs of these hub genes could
be co-regulated by some common miRNAs. It is still unknown
how the co-regulating feature in transcription is associated with
the co-regulating feature in translation, however, the predicted
conserved promoter motifs and common miRNAs suggest that
some regulatory elements within these genes are phylogenetically
conserved. This is consistent to the finding that the violet module
has a genetic basis. Interestingly, three hub genes (ENO3, ISOC1
and GNB3) in this cluster were enriched in the first annotation
(hereditary disorder) and/or the second annotation (neurological
disease) of diseases and functions. Moreover, they were three
highly ranked hub genes of the violet module and some SNPs
around them were APOE ε4 carrier-specific (Supplementary
Tables S3 and S24). One SNP, rs5443 within GNB3, has been
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reported to correlate with increased APP expression (Bullido
et al., 2004). In addition, this SNP is located within one of the ten
most interesting genetic linkage regions related to AD (Guerreiro
et al., 2012). Thus, we propose that these three genes could play
important roles in AD APOE ε4 carriers with a genetic basis and
also in a co-regulated manner.
Genes within the violet module of AD APOE ε4 carriers
were mainly enriched in energy metabolism-associated signaling
pathways. Energy metabolism and the expression of energy
metabolism-associated genes are reported to be decreased in AD
patients (Liang et al., 2008). However, the decrease in energy
metabolism is even worse in APOE ε4 carriers who manifest it
before AD development (Reiman et al., 2005; Wolf et al., 2013).
Acetyl-CoA is a key intermediate in energy metabolism and also a
key precursor for acetylcholine synthesis. It is almost exclusively
synthesized in mitochondria from the pyruvate dehydrogenase
complex (PDHC) reaction in the brain. It has been found that the
activities of PDHC and choline acetyl transferase for acetylcholine
synthesis are strongly suppressed in the brain cortexes of AD
APOE ε4 carriers (Gibson et al., 2000; Bubber et al., 2005).
Moreover, decreased acetyl-CoA for acetylcholine synthesis is
responsible for decreased transmitter functions in cholinergic
neurons of AD patients (Szutowicz et al., 2013). Furthermore,
in mice expressing human APOE ε4, evoked hippocampal
acetylcholine release is reduced (Dolejsi et al., 2016). Thus, our
findings explain the pathological differences between AD APOE
ε4 carriers and non-carriers.
Genes within the dark magenta module of AD APOE ε4
carriers were mainly enriched in GPCRs and their second
messengers-associated signaling pathways. Actually, many
GPCRs have been validated to take part in the pathological
process of AD, such as muscarinic acetylcholine receptors (M
receptors) and metabotropic glutamate receptors (Albasanz
et al., 2005; Wess et al., 2007). M2 and M4 receptors seem to
inhibit the soluble amino-terminal ectodomain of APP (sAPPα)
release and potentially aggravate Aβ generation (Farber et al.,
1995). Deletion of M1 receptors is responsible for increased
amyloid pathology (Davis et al., 2010). However, some specific
phenomena are observed in APOE ε4 carriers. The density of
M2 receptor is specifically higher in some cerebral regions of
healthy APOE ε4 carriers compared to non-carriers (Cohen et al.,
2003). Facilitating brain noradrenergic and vasopressinergic
activities improves cognitive function only in AD APOE ε4
carriers (Richard et al., 1997). Defects in GPCRs, especially M
receptors, have been widely reported in AD; however, the related
signaling pathways were specifically enriched in AD APOE ε4
carriers. Thus, we hypothesize that alterations in GPCRs could
play critical pathogenic and pathological roles in APOE ε4
carriers.
The genes in the light cyan module identified in AD APOE
ε4 non-carriers were enriched not only in neurological diseases
but also in some other types of diseases, such as immunological
and cardiovascular diseases with high rankings. Furthermore,
many genes were enriched in all of these diseases. However, these
phenomena were not observed in AD APOE ε4 carriers. The
involvement of the immune system in the pathogenesis of AD
has long been demonstrated (Akiyama, 1994). Cardiovascular
diseases have been reported to share some common risk factors
and common signaling pathways with AD (Martins et al.,
2006). Moreover, this module was enriched in various signaling
pathways. tRNA charging is part of protein synthesis, TR/RXR
regulates gene expression, and TNFR1 is a receptor for TNFα
which is a potent proinflammatory cytokine. ER stress, retinoid
signaling and TNFR1 are reported to be associated with AD
(Corcoran et al., 2004; de la Monte et al., 2012; Laske et al.,
2013). ER stress could enhance the production of Aβ (Liu et al.,
2014). ER stress is also involved in tauopathy (Sakagami et al.,
2013). Activation of retinoid acid receptors and RXR can up-
regulate α-secretase ADAM10 (Tippmann et al., 2009). RXR
can form heterodimers with peroxisome proliferator-activated
receptor γ (PPARγ), and their combined activation cooperatively
enhances the microglial uptake of Aβ (Yamanaka et al., 2012).
TR and RXR can up-regulate the mRNA of an AD-associated
gene (Ishida et al., 2013). TNFR1 is up-regulated in AD brains
and is required in Aβ-induced neuronal apoptosis and cognitive
impairment (Li et al., 2004; Cheng et al., 2010; Lourenco et al.,
2013). However, these signaling pathways are not limited to AD.
They are also involved in many pathological processes of various
diseases such as cardiovascular diseases, immunological diseases,
PD, and inflammation (Yoshida, 2007; Van Hauwermeiren et al.,
2011; Nizamutdinova et al., 2013). Thus, these data indicate
that the development of AD in APOE ε4 non-carriers may not
stem from unique pathogenic processes, but rather, AD shares
some common pathways or develops concomitantly with other
types of diseases. However, our findings do not preclude the
probable effects of APOE ε4 on these signaling pathways, such
as pathways of the immune systems, which have been previously
demonstrated (Keene et al., 2011).
To further validate our results, we selected PD and BD,
two brain diseases with some common clinical or pathological
relationships with AD. Pathologically PD and AD are very
similar, as both types of patients exhibit senile plaques and
fibrillary tangles. Cognitive deficits in PD are attributed to the
prefrontal cortex (Fuster, 2000), and PT and SN are responsible
for extrapyramidal signs (Rinne et al., 1989). Our results
demonstrated that the purple module detected in BA9 of the
prefrontal cortex of PD patients was highly correlated with the
light cyan module of AD APOE ε4 non-carriers, and such a
correlation was not observed in PT and SN, suggesting the
relationship of cognitive deficits between AD and PD. Thus, our
data not only provide the evidence of the validity of the light
cyan module but also demonstrate a relationship between PD
and AD, especially the close relationship between PD and AD
of APOE ε4 non-carriers. However, our data are not consistent
with a previous study, which failed to detect any overlapping
genes between AD and PD (Talwar et al., 2014). Because we
demonstrated the difference between AD APOE ε4 carriers and
non-carriers and because no risk genes were found in PD to play
such a significant role as APOE ε4 in AD, the disparity could be
attributed to the fact that the authors of the previous study did
not stratify the AD samples according to APOE status. Although
BD also shares some common characteristics with AD, especially
at a later stage during disease progression, few studies have
reported overlapping genes between AD and BD. In our study,
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disease-specific modules displayed no correlations between BD
and AD. Thus, we propose that the clinical and pathological
overlap between AD and BD could be due to downstream
cascades from pathogenic factors of each disease. However, our
study does not preclude the possible harmful effects of APOE ε4
on PD and BD which have been reported even though APOE ε4
is unlikely a strong risk factor for PD and BD (Soeira-de-Souza
et al., 2010; Monsell et al., 2014).
The three modules identified did not show any evidence
of correlation with aging (data not shown), the commonly
acknowledged risk factor for AD. Infants carrying APOE ε4 have
different temporal cortex structures compared to APOE ε4 non-
carriers (Knickmeyer et al., 2014), and a similar difference was
also observed in adults (Hua et al., 2008). Multiple approaches
utilizing mice and humans have demonstrated that APOE ε4 can
affect normal brain function even very early in life (DiBattista
et al., 2016). Thus, the identified modules may exert roles in
an age-independent manner which may take effect or promote
disease progression at an early age.
In summary, the present study demonstrated that AD APOE
ε4 carriers involve more genetic factors and that particular
biological processes may exert pathogenic effects, whereas AD
APOE ε4 non-carriers share more common pathways with
other types of diseases, and AD may develop accompanying
these diseases. Although some of the identified hub genes,
signaling pathways, TFs and miRNAs are known to be AD-
associated, our data further demonstrated that they are likely
specifically associated with AD APOE ε4 carriers or non-carriers.
Moreover, our study may help to uncover the function of poorly
characterized hub gene(s), as WGCNA may reveal the functions
of genes if they are in a module highly enriched in a particular
biological process (Chen et al., 2013). Our study provides new
insights into the pathogenic and pathological mechanisms other
than those of APOE4, underlying the different characteristics of
AD APOE ε4 carriers and non-carriers, which may open a new
avenue for the further investigation of AD and might promote
the differential treatment of AD based on APOE ε4 status.
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